Genomewide interaction and enrichment analysis on antidepressant response

Psychological Medicine

Volumn 44, Issue 4, 2014, Pages 753-765

  Antypa, N ^a   Drago, A ^b   Serretti, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Antidepressant response; Enrichment analysis; Genomewide interaction; Quality of life

Indexed keywords

ANTIDEPRESSANT AGENT; ESCRT PROTEIN; NEDD4 UBIQUITIN PROTEIN LIGASES; UBIQUITIN PROTEIN LIGASE;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); DEPRESSION; FEMALE; GENETIC ASSOCIATION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PHARMACOGENETICS; PREDICTIVE VALUE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSION; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FEMALE; GENE-ENVIRONMENT INTERACTION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; UBIQUITIN-PROTEIN LIGASES;

EID: 84896451365     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291713001554     Document Type: Article

References (67)

1. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT (2010). Data quality control in genetic case-control association studies. Nature Protocols 5, 1564-1573
2. Appel K, Schwahn C, Mahler J, Schulz A, Spitzer C, Fenske K, Stender J, Barnow S, John U, Teumer A, Biffar R, Nauck M, Volzke H, Freyberger HJ, Grabe HJ (2011). Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology 36, 1982-1991
3. Araki N, Umemura M, Miyagi Y, Yabana M, Miki Y, Tamura K, Uchino K, Aoki R, Goshima Y, Umemura S, Ishigami T (2008). Expression, transcription, and possible antagonistic interaction of the human Nedd4L gene variant; implications for essential hypertension. Hypertension 51, 773-777
4. Baron M (2002). Manic-depression genes and the new millennium: Poised for discovery. Molecular Psychiatry 7, 342-358
5. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T, Kunzel HE, Fuchs B, Majer M, Pfennig A, Kern N, Brunner J, Modell S, Baghai T, Deiml T, Zill P, Bondy B, Rupprecht R, Messer T, Kohnlein O, Dabitz H, Bruckl T, Muller N, Pfister H, Lieb R, Mueller JC, Lohmussaar E, Strom TM, Bettecken T, Meitinger T, Uhr M, Rein T, Holsboer F, Muller-Myhsok B (2004). Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nature Genetics 36, 1319-1325
6. Booij L, Van Der Does W, Benkelfat C, Bremner JD, Cowen PJ, Fava M, Gillin C, Leyton M, Moore P, Smith KA, Van Der Kloot WA (2002). Predictors of mood response to acute tryptophan depletion. A reanalysis. Neuropsychopharmacology 27, 852-861
7. Cohen RM, Greenberg JM, Ishak WW (2013). Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the individual burden of illness index for depression to measure treatment impact and recovery in MDD. Journal of the American Medical Association Psychiatry 70, 343-350
8. Cohen-Woods S, Craig IW, McGuffin P (2013). The current state of play on the molecular genetics of depression. Psychological Medicine 43, 673-687
9. Cornelis MC, Tchetgen EJ, Liang L, Qi L, Chatterjee N, Hu FB, Kraft P (2012). Gene-environment interactions in genome-wide association studies: A comparative study of tests applied to empirical studies of type 2 diabetes. American Journal of Epidemiology 175, 191-202
10. Daly EJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Gaynes BN, Warden D, Morris DW, Luther JF, Farabaugh A, Cook I, Rush AJ (2010). Health-related quality of life in depression: A STAR.D report. Annals of Clinical Psychiatry 22, 43-55
11. Drago A, De Ronchi D, Serretti A (2009). Pharmacogenetics of antidepressant response: An update. Human Genomics 3, 257-274
12. Drago A, Serretti A (2011). Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: A comparison between the STAR D study and an independent trial. Journal of Clinical Psychopharmacology 31, 345-348
13. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin 29, 321-326
14. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ (2003). Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR.D) study. Psychiatric Clinics of North America 26, 457-494
15. Fishell G, Hatten ME (1991). Astrotactin provides a receptor system for CNS neuronal migration. Development 113, 755-765
16. Flint J, Munafo MR (2013). Candidate and non-candidate genes in behavior genetics. Current Opinion in Neurobiology 23, 57-61
17. Franchini L, Serretti A, Gasperini M, Smeraldi E (1998). Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatric Research 32, 255-259
18. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP (2010). A genomewide association study of citalopram response in major depressive disorder. Biological Psychiatry 67, 133-138
19. Ge D, Zhang K, Need AC, Martin O, Fellay J, Urban TJ, Telenti A, Goldstein DB (2008). WGAViewer: Software for genomic annotation of whole genome association studies. Genome Research 18, 640-643
20. Harding MW, Galat A, Uehling DE, Schreiber SL (1989). A receptor for the immunosuppressant FK506 is a cis-Trans peptidyl-prolyl isomerase. Nature 341, 758-760
21. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Muller-Myhsok B, Holsboer F, Binder EB (2010). Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35, 727-740
22. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Muller-Myhsok B (2009). A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Archives of General Psychiatry 66, 966-975
23. Karg K, Sen S (2012). Gene x environment interaction models in psychiatric genetics. Current Topics in Behavioral Neurosciences 12, 441-462
24. Kato M, Serretti A (2010). Review and meta-Analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 15, 473-500
25. Keers R, Uher R (2012). Gene-environment interaction in major depression and antidepressant treatment response. Current Psychiatry Reports 14, 129-137
26. Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S, Rietschel M, Henigsberg N, Kozel D, Mors O, Maier W, Zobel A, Hauser J, Souery D, Placentino A, Larsen ER, Dmitrzak-Weglarz M, Gupta B, Hoda F, Craig I, McGuffin P, Farmer AE, Aitchison KJ (2011). Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics Journal 11, 138-145
27. Khoury MJ, Wacholder S (2009). Invited commentary: From genome-wide association studies to gene-environmentwide interaction studies-challenges and opportunities. American Journal of Epidemiology 169, 227-230
28. Kirchheiner J, Lorch R, Lebedeva E, Seeringer A, Roots I, Sasse J, Brockmöller J (2008). Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 9, 841-846
29. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, Yamanouchi Y, Kinoshita Y, Kawashima K, Naitoh H, Nakamura J, Ozaki N, Iwata N (2010). HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Medicine 12, 237-242
30. Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS (2010). Nuclear factor-?B is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proceedings of the National Academy of Sciences USA 107, 2669-2674
31. Kristjansson K, Manolescu A, Kristinsson A, Hardarson T, Knudsen H, Ingason S, Thorleifsson G, Frigge ML, Kong A, Gulcher JR, Stefansson K (2002). Linkage of essential hypertension to chromosome 18q. Hypertension 39, 1044-1049
32. Laje G, Perlis RH, Rush AJ, McMahon FJ (2009). Pharmacogenetics studies in STAR D: Strengths, limitations, and results. Psychiatric Services 60, 1446-1457
33. LaPlant Q, Chakravarty S, Vialou V, Mukherjee S, Koo JW, Kalahasti G, Bradbury KR, Taylor SV, Maze I, Kumar A, Graham A, Birnbaum SG, Krishnan V, Truong HT, Neve RL, Nestler EJ, Russo SJ (2009). Role of nuclear factor ?B in ovarian hormone-mediated stress hypersensitivity in female mice. Biological Psychiatry 65, 874-880
34. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ, Paddock S (2008). The FKBP5-gene in depression and treatment response-An association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR D) cohort. Biological Psychiatry 63, 1103-1110
35. Licht CM, de Geus EJ, Seldenrijk A, van Hout HP, Zitman FG, Van Dyck R, Penninx BW (2009). Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 53, 631-638
36. Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, Muller-Myhsok B, Holsboer F, Domschke K (2010). HTR2A gene variation is involved in antidepressant treatment response. European Neuropsychopharmacology 20, 65-68
37. Malhotra AK (2010). The pharmacogenetics of depression; enter the GWAS. American Journal of Psychiatry 167, 493-495
38. Mandelli L, Marino E, Pirovano A, Calati R, Zanardi R, Colombo C, Serretti A (2009). Interaction between SERTPR and stressful life events on response to antidepressant treatment. European Neuropsychopharmacology 19, 64-67
39. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 78, 804-814
40. Murcray CE, Lewinger JP, Conti DV, Thomas DC, Gauderman WJ (2011). Sample size requirements to detect gene-environment interactions in genome-wide association studies. Genetic Epidemiology 35, 201-210
41. Nwulia EA, Miao K, Zandi PP, Mackinnon DF, DePaulo Jr. JR, McInnis MG (2007). Genome-wide scan of bipolar II disorder. Bipolar Disorders 9, 580-588
42. O'Reilly RL, Bogue L, Singh SM (1994). Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biological Psychiatry 36, 467-471
43. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ (2007). Association of GRIK4 with outcome of antidepressant treatment in the STAR D cohort. American Journal of Psychiatry 164, 1181-1188
44. Papakostas GI, Fava M (2008). Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues in Clinical Neuroscience 10, 439-451
45. Papakostas GI, Fava M (2009). Does the probability of receiving placebo influence clinical trial outcome?. A meta-regression of double-blind, randomized clinical trials in MDD. European Neuropsychopharmacology 19, 34-40
46. Phipson B, Smyth GK (2010). Permutation P-values should never be zero: Calculating exact P-values when permutations are randomly drawn. Statistical Applications in Genetics and Molecular Biology 9, 39
47. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A (2011). Pharmacogenetics of antidepressant response. Journal of Psychiatry and Neuroscience 36, 87-113
48. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nature Genetics 38, 904-909
49. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007). PLINK: A tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics 81, 559-575
50. Pyne JM, Bullock D, Kaplan RM, Smith TL, Gillin JC, Golshan S, Kelsoe JR, Williams DK (2001). Health-related quality-of-life measure enhances acute treatment response prediction in depressed inpatients. Journal of Clinical Psychiatry 62, 261-268
51. Ritsner M, Kurs R, Gibel A, Ratner Y, Endicott J (2005). Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Quality of Life Research 14, 1693-1703
52. Rush AJ, Trivedi M, Fava M (2003). Depression, IV: STAR D treatment trial for depression. American Journal of Psychiatry 160, 237
53. Serretti A, Benedetti F, Zanardi R, Smeraldi E (2005). The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Progress in Neuro-psychopharmacology and Biological Psychiatry 29, 1074-1084
54. Siddiqui NU, Li X, Luo H, Karaiskakis A, Hou H, Kislinger T, Westwood JT, Morris Q, Lipshitz HD (2012). Genome-wide analysis of the maternal-To-zygotic transition in Drosophila primordial germ cells. Genome Biology 13, R11
55. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J (2007). Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study. Journal of Clinical Psychiatry 68, 1062-1070
56. Svensson-Fdrbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, Hedner T, Melander O (2011). A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients. Journal of Hypertension 29, 388-395
57. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M (2006a). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR D: Implications for clinical practice. American Journal of Psychiatry 163, 28-40
58. Trivedi MH, Rush AJ, Wisniewski SR, Warden D, McKinney W, Downing M, Berman SR, Farabaugh A, Luther JF, Nierenberg AA, Callan JA, Sackeim HA (2006b). Factors associated with health-related quality of life among outpatients with major depressive disorder: A STAR D report. Journal of Clinical Psychiatry 67, 185-195
59. Uher R (2011). Genes, environment, and individual differences in responding to treatment for depression. Harvard Review of Psychiatry 19, 109-124
60. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, Hauser J, Maier W, Kozel D, Henigsberg N, Barreto M, Placentino A, Dernovsek MZ, Schulze TG, Kalember P, Zobel A, Czerski PM, Larsen ER, Souery D, Giovannini C, Gray JM, Lewis CM, Farmer A, Aitchison KJ, McGuffin P, Craig I (2009). Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal 9, 225-233
61. Uher R, McGuffin P (2010). The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Molecular Psychiatry 15, 18-22
62. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P (2010). Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. American Journal of Psychiatry 167, 555-564
63. Weiss LA, Arking DE, Daly MJ, Chakravarti A (2009). A genome-wide linkage and association scan reveals novel loci for autism. Nature 461, 802-808
64. Wilson PM, Fryer RH, Fang Y, Hatten ME (2010). Astn2, a novel member of the astrotactin gene family, regulates the trafficking of ASTN1 during glial-guided neuronal migration. Journal of Neuroscience 30, 8529-8540
65. Wong ML, Dong C, Andreev V, Arcos-Burgos M, Licinio J (2012). Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environmental factors. Molecular Psychiatry 17, 624-633
66. Zheng C, Heintz N, Hatten ME (1996). CNS gene encoding astrotactin, which supports neuronal migration along glial fibers. Science 272, 417-419
67. Zimmermann P, Bruckl T, Nocon A, Pfister H, Binder EB, Uhr M, Lieb R, Moffitt TE, Caspi A, Holsboer F, Ising M (2011). Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: Results from a 10-year prospective community study. American Journal of Psychiatry 168, 1107-1116